glp-1 retatrutide Doctor’s WARNING: The Dark Side of Weight Loss (Is WORSE Than Tirzepatide?) Gwyneth Paltrow, Andrew Huberman &

Can the dose be adjusted during treatment

Lower treatment burden While retatrutide shows significant promise, Eli Lilly is likely to disrupt the market more imminently and more substantially following the launch of orforglipron in early 2026

Among all medicines worldwide, treatments for obesity and diabetes featuring GLP-1 agonists have surged to the top of the best-seller lists in the first half of 2025

He Z, Gao Y, Lieu L, Afrin S, Cao J, Michael NJ, et al

Meaning, you should have the same treatment experience taking generic liraglutide as you would with brand-name Saxenda

While specific requirements can vary by provider, clients are commonly considered good candidates if they meet one of the following criteria: A BMI of 30 or higher (classified as obesity) A BMI of 27 or higher with at least one weight-related health condition, such as high blood pressure, high cholesterol, type 2 diabetes, prediabetes, or sleep apnea In addition, candidates should be in overall stable health, not pregnant or breastfeeding, and not have a personal or family history of certain medical conditions such as medullary thyroid carcinoma or MEN2 (Multiple Endocrine Neoplasia type 2)